Pharmaceutical

NephroDI Therapeutics and MSRD partner to develop therapy for NDI

NephroDI Therapeutics has signed a deal with the McQuade Center for Strategic Research and Development (MSRD) for the development of NDI-5001

Jun 23, 2023 - 20:00
NephroDI Therapeutics and MSRD partner to develop therapy for NDI
NephroDI Therapeutics has signed a deal with the McQuade Center for Strategic Research and Development (MSRD) for the development of NDI-5001
Read the original article

Tags:

Previous Article

FDA approves Duchenne gene therapy with hefty $3.2m price tag

Next Article

BMS and Eurofins invest in Indian pharma hubs Andhra Pradesh and Telangana

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The biotech updates you need to read today

The biotech updates you need to read today

Dec 19, 2023

Biotheryx and Incyte sign agreement to develop protein degraders for oncology

Biotheryx and Incyte sign agreement to develop protein ...

Apr 6, 2023

OSE Immunotherapeutics’ Tedopi gains US patent for cancer treatment

OSE Immunotherapeutics’ Tedopi gains US patent for canc...

Jul 5, 2023